Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Keratitis --- Corneal Stroma --- Cornea --- Aldehyde Dehydrogenase --- Antigen-Antibody Complex --- immunology --- immunology --- immunology --- chemistry --- metabolism

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The Special Issue on high grade serous ovarian cancer (HGSOC) and the contribution of the tumor microenviroment (TME) consists of reviews contributed by leaders in the OC field. As HGSOC metastases have a highly complex TME, there is an urgent need to better understand the TME in general, its distinct components in particular, and the role of the TME in the context of disease recurrence and development of chemoresistance. The Special Issue incorporates the current understanding of the different parts of thd TME components, including the cancer cells themselves, the cells surrounding the cancer cells or stromal cells, and the cells of the immune system, which are attracted to the site of metastases. In addition to these cells of the TME, the role of various cellular factors made by the cells of the TME are also the subject of the reviews. In addition, reviews in this Special Issue cover the complex relationships between the molecular mechanisms of HGSOC progression, including genomic, epigenomic and transcriptomic changes and changes in the immune cell landscape, as these may provide attractive new molecular targets for HGSOC therapy.

ovarian cancer --- transcriptomic --- stroma --- immune cells --- epigenetics --- recurrence --- immunotherapies --- chemoresistance --- fibroblasts --- metastasis --- genomic --- tumor microenvironment --- cancer stem cells

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Personalised medicine is the next step in healthcare, especially when applied to genetically diverse diseases such as cancers. Naturally, a host of methods need to evolve alongside this, in order to allow the practice and implementation of individual treatment regimens. One of the major tasks for the development of personalised treatment of cancer is the identification and validation of a comprehensive, robust, and reliable panel of biomarkers that guide the clinicians to provide the best treatment to patients. This is indeed important with regards to radiotherapy; not only do biomarkers allow for the assessment of treatability, tumour response, and the radiosensitivity of healthy tissue of the treated patient. Furthermore, biomarkers should allow for the evaluation of the risks of developing adverse late effects as a result of radiotherapy such as second cancers and non-cancer effects, for example cardiovascular injury and cataract formation. Knowledge of all of these factors would allow for the development of a tailored radiation therapy regime. This Special Issue of the Journal of Personalised Medicine covers the topic of Radiation Response Biomarkers in the context of individualised cancer treatments, and offers an insight into some of the further evolution of radiation response biomarkers, their usefulness in guiding clinicians, and their application in radiation therapy.

Medicine --- carbon-ion radiotherapy --- head-and-neck tumors --- squamous cell carcinoma --- radiosensitivity --- relative biological effectiveness --- lung cancer --- radiotherapy --- radiotherapy monitoring --- radiation-induced lung injury --- RILI --- pneumonitis --- radiation-induced lung fibrosis --- RILF --- circulating biomarkers --- microRNA --- micronuclei --- uterine cervical cancer --- cGAS --- STING --- abscopal effect --- immunotherapy --- PBMCS --- micronucleus assay --- biological dosimetry --- human blood --- genotoxicity tests --- ionizing radiation --- biomarkers --- dicentric assay --- gamma H2AX foci assay --- health surveillance analyses --- clonogenic assays --- methods --- plating --- cancer --- radiation --- head and neck cancer --- exosomes --- serum --- metabolomics --- GC/MS --- biodosimetry --- chromosome aberrations --- normal tissue toxicity --- predictive tests --- normal tissue --- biomarker --- protein --- immune infiltrate --- stroma --- tumour microenvironment --- proteomics --- telomeres --- chromosomal instability --- inversions --- prostate cancer --- IMRT --- machine learning --- individual radiosensitivity --- late effects --- personalized medicine --- liquid biopsy --- circulating tumour cells --- extracellular vesicles --- microRNAs --- immune system --- inflammation --- carbon-ion radiotherapy --- head-and-neck tumors --- squamous cell carcinoma --- radiosensitivity --- relative biological effectiveness --- lung cancer --- radiotherapy --- radiotherapy monitoring --- radiation-induced lung injury --- RILI --- pneumonitis --- radiation-induced lung fibrosis --- RILF --- circulating biomarkers --- microRNA --- micronuclei --- uterine cervical cancer --- cGAS --- STING --- abscopal effect --- immunotherapy --- PBMCS --- micronucleus assay --- biological dosimetry --- human blood --- genotoxicity tests --- ionizing radiation --- biomarkers --- dicentric assay --- gamma H2AX foci assay --- health surveillance analyses --- clonogenic assays --- methods --- plating --- cancer --- radiation --- head and neck cancer --- exosomes --- serum --- metabolomics --- GC/MS --- biodosimetry --- chromosome aberrations --- normal tissue toxicity --- predictive tests --- normal tissue --- biomarker --- protein --- immune infiltrate --- stroma --- tumour microenvironment --- proteomics --- telomeres --- chromosomal instability --- inversions --- prostate cancer --- IMRT --- machine learning --- individual radiosensitivity --- late effects --- personalized medicine --- liquid biopsy --- circulating tumour cells --- extracellular vesicles --- microRNAs --- immune system --- inflammation

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Personalised medicine is the next step in healthcare, especially when applied to genetically diverse diseases such as cancers. Naturally, a host of methods need to evolve alongside this, in order to allow the practice and implementation of individual treatment regimens. One of the major tasks for the development of personalised treatment of cancer is the identification and validation of a comprehensive, robust, and reliable panel of biomarkers that guide the clinicians to provide the best treatment to patients. This is indeed important with regards to radiotherapy; not only do biomarkers allow for the assessment of treatability, tumour response, and the radiosensitivity of healthy tissue of the treated patient. Furthermore, biomarkers should allow for the evaluation of the risks of developing adverse late effects as a result of radiotherapy such as second cancers and non-cancer effects, for example cardiovascular injury and cataract formation. Knowledge of all of these factors would allow for the development of a tailored radiation therapy regime. This Special Issue of the Journal of Personalised Medicine covers the topic of Radiation Response Biomarkers in the context of individualised cancer treatments, and offers an insight into some of the further evolution of radiation response biomarkers, their usefulness in guiding clinicians, and their application in radiation therapy.

carbon-ion radiotherapy --- head-and-neck tumors --- squamous cell carcinoma --- radiosensitivity --- relative biological effectiveness --- lung cancer --- radiotherapy --- radiotherapy monitoring --- radiation-induced lung injury --- RILI --- pneumonitis --- radiation-induced lung fibrosis --- RILF --- circulating biomarkers --- microRNA --- micronuclei --- uterine cervical cancer --- cGAS --- STING --- abscopal effect --- immunotherapy --- PBMCS --- micronucleus assay --- biological dosimetry --- human blood --- genotoxicity tests --- ionizing radiation --- biomarkers --- dicentric assay --- gamma H2AX foci assay --- health surveillance analyses --- clonogenic assays --- methods --- plating --- cancer --- radiation --- head and neck cancer --- exosomes --- serum --- metabolomics --- GC/MS --- biodosimetry --- chromosome aberrations --- normal tissue toxicity --- predictive tests --- normal tissue --- biomarker --- protein --- immune infiltrate --- stroma --- tumour microenvironment --- proteomics --- telomeres --- chromosomal instability --- inversions --- prostate cancer --- IMRT --- machine learning --- individual radiosensitivity --- late effects --- personalized medicine --- liquid biopsy --- circulating tumour cells --- extracellular vesicles --- microRNAs --- immune system --- inflammation --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The book is based on the Cancers journal Special Issue entitled “Immunotherapy, Tumor Microenvironment and Survival Signaling", and focuses on important problems concerning tumors and tumor microenvironment interactions, as well as novel immunotherapies such as CAR-T cell therapy. Immunotherapies have recently shown remarkable results in the treatment of cancer patients. However, there are still many questions that remain to be solved in regards to more effective therapies, such as the tumor heterogeneous profile, tumor microenvironment, and tumor survival epigenetic and genetic pathways, all of which make patients resistant to the presently available treatments for cancer. This book demonstrates different approaches to overcome the challenges faced by immunotherapies due to suppressive tumor microenvironments. This book includes 18 papers that can be divided into three chapters: 1. novel immunotherapies; 2. targeting tumor microenvironment and novel approaches; 3. targeting tumors and tumor microenvironment in different types of cancer.

Medicine --- Clinical & internal medicine --- Autophagy --- colorectal cancer --- immunotherapy --- tumor stroma --- tumor microenvironment --- immune checkpoint inhibitors --- chemotherapy --- tyrosine kinase inhibitors --- angiogenesis --- check point inhibitors --- programmed cell death protein 1 --- programmed cell death 1 ligand 1 --- cardiotoxicity --- lung metastasis --- CAR-T --- hypoxia --- tumor --- microenvironment --- CD19 --- BCMA --- cancer --- melanoma --- immune escape --- antigen loss --- chimeric antigen receptor --- electroporation --- lentivirus --- lentiviral transduction --- macrophages --- leukemia cells --- lytic peptides --- targeted therapy --- dendritic cells --- pathogenesis --- risk factors --- breast cancer --- resistance --- checkpoint --- targeted treatment --- personalized medicine --- pediatric solid tumors --- chimeric antigen receptors --- cancer vaccines --- oncolytic viral therapy --- immunomodulation --- DCLK1 --- tumor stem cells --- clonogenicity --- mitochondria --- mitochondrial transfer --- tunneling nanotubes --- triple-negative breast cancer --- immune checkpoint inhibitor --- combination therapy --- cancer nanomedicine --- tumor antigens --- cancer metabolism --- cancer immunotherapy --- nanoparticles --- immunotherapeutic agent --- immunomodulators --- tuft cells --- cancer stem cells --- immunotherapies --- myeloid-derived suppressor cells --- regulatory T cells --- crosstalk --- tumor immune evasion --- cell-cell contact --- β2 integrins --- CD18 --- CD11 --- CAR-T cells --- CD37 --- cell therapy --- tumor antigen --- lymphoma --- CAR macrophage --- CAR T cell --- solid tumors --- immunometabolism --- miRNA --- immunogenic cell death --- Autophagy --- colorectal cancer --- immunotherapy --- tumor stroma --- tumor microenvironment --- immune checkpoint inhibitors --- chemotherapy --- tyrosine kinase inhibitors --- angiogenesis --- check point inhibitors --- programmed cell death protein 1 --- programmed cell death 1 ligand 1 --- cardiotoxicity --- lung metastasis --- CAR-T --- hypoxia --- tumor --- microenvironment --- CD19 --- BCMA --- cancer --- melanoma --- immune escape --- antigen loss --- chimeric antigen receptor --- electroporation --- lentivirus --- lentiviral transduction --- macrophages --- leukemia cells --- lytic peptides --- targeted therapy --- dendritic cells --- pathogenesis --- risk factors --- breast cancer --- resistance --- checkpoint --- targeted treatment --- personalized medicine --- pediatric solid tumors --- chimeric antigen receptors --- cancer vaccines --- oncolytic viral therapy --- immunomodulation --- DCLK1 --- tumor stem cells --- clonogenicity --- mitochondria --- mitochondrial transfer --- tunneling nanotubes --- triple-negative breast cancer --- immune checkpoint inhibitor --- combination therapy --- cancer nanomedicine --- tumor antigens --- cancer metabolism --- cancer immunotherapy --- nanoparticles --- immunotherapeutic agent --- immunomodulators --- tuft cells --- cancer stem cells --- immunotherapies --- myeloid-derived suppressor cells --- regulatory T cells --- crosstalk --- tumor immune evasion --- cell-cell contact --- β2 integrins --- CD18 --- CD11 --- CAR-T cells --- CD37 --- cell therapy --- tumor antigen --- lymphoma --- CAR macrophage --- CAR T cell --- solid tumors --- immunometabolism --- miRNA --- immunogenic cell death